MS and Demyelinating Disorders

Updated results to the phase 3 CHAMPION-NMOSD trial of ravulizumab showed significantly lower HAI score worsening following treatment.

After 228 weeks of treatment, annualized relapse rates favored twice-daily 75 mg dosing of evobrutinib vs once-daily.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Academy of Neurology.

There were no observed tolebrutinib dose effect for treatment-emergent adverse events in the double-blind portion, as well as no new safety signals seen for those who crossed over in the open-label extension.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 21, 2023.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Robert Zivadinov, MD, PhD. [LISTEN TIME: 30 minutes]

NMOSD-related optic neuritis represented the strongest predictive risk factor of failure to attain visual recovery of at least 0.3 logMAR, with an odds ratio of 10.47.

Collectively, the results suggested that multiple sclerosis and migraine may co-occur because they share several genetic variants, rather than migraine causing MS.

Sheryl Lapidus, MA, senior director of patient advocacy at Horizon Therapeutics, talked about the findings from a recently conducted patient survey on NMOSD and the importance of advocacy in the field.

CSL Behring's subcutaneous immune globulin is the first and only immune globulin available in prefilled syringes for patients with primary immunodeficiency or chronic inflammatory demyelinating polyneuropathy.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke and cerebrovascular disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 14, 2023.

Evobrutinib, a highly selective BTK inhibitor, has previously demonstrated positive impacts on relapse rates and neurofilament light in patients with relapsing multiple sclerosis.

On average, across all levels of physical fatigue, participants would accept a 0.32 year decrease in time to multiple sclerosis progression in exchange for a 3.57-point change in FSIQ-RMS-S score.

Drs Ahmed Zayed and Mark S. Freedman review emerging therapies in the pipeline and unmet needs in the multiple sclerosis treatment landscape, as well as take-home thoughts.

Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, provides an overview of the different types of Bruton tyrosine kinase inhibitors (BTKi) in management of MS.

Experts in neurology highlight the factors they consider when switching treatments for a patient with MS.

The immunology fellow at Brigham and Women’s Hospital discussed the current state of care for patients with MOGAD, and whether treatment decisions differ based on timing of attacks. [WATCH TIME: 7 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis (MS).

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 7, 2023.

The National Multiple Sclerosis Society’s CME program follows Project ECHO’s evidence-based telementoring model and establishes a peer-to-peer knowledge sharing network.

Michael Levy, MD, PhD, associate professor at Harvard Medical School, spoke about the breakthrough of drugs for NMOSD and the challenges patients face to receive treatment.

More than 95% of the cohort of elderly patients showed functional improvement at 6 months after plasma exchange, including 60% who experienced moderate-to-marked improvement.